Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Baxter
Medtronic
Merck
Colorcon

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR ENALAPRIL MALEATE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Enalapril Maleate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000522 ↗ Treatment of Mild Hypertension Study (TOMHS) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 1985-08-01 To compare the effects of nonpharmacologic therapy alone with those of one of five active drug regimens combined with non-pharmacologic therapy, for long- term management of patients with mild hypertension.
NCT00000522 ↗ Treatment of Mild Hypertension Study (TOMHS) Completed University of Minnesota Phase 2 1985-08-01 To compare the effects of nonpharmacologic therapy alone with those of one of five active drug regimens combined with non-pharmacologic therapy, for long- term management of patients with mild hypertension.
NCT00000522 ↗ Treatment of Mild Hypertension Study (TOMHS) Completed University of Minnesota - Clinical and Translational Science Institute Phase 2 1985-08-01 To compare the effects of nonpharmacologic therapy alone with those of one of five active drug regimens combined with non-pharmacologic therapy, for long- term management of patients with mild hypertension.
NCT00003070 ↗ Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer Completed National Cancer Institute (NCI) Phase 3 2000-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as enalapril, may protect normal cells from the toxic effects of chemotherapy. It is not known whether enalapril is more effective than a placebo in treating heart damage in patients who received anthracycline chemotherapy for childhood cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of enalapril with a placebo in treating heart damage in patients who received anthracycline chemotherapy for childhood cancer.
NCT00003070 ↗ Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer Completed Children's Oncology Group Phase 3 2000-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as enalapril, may protect normal cells from the toxic effects of chemotherapy. It is not known whether enalapril is more effective than a placebo in treating heart damage in patients who received anthracycline chemotherapy for childhood cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of enalapril with a placebo in treating heart damage in patients who received anthracycline chemotherapy for childhood cancer.
NCT00568178 ↗ An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2)) Completed Merck Sharp & Dohme Corp. Phase 3 2007-06-01 The purpose of this study is to evaluate the effects of losartan on proteinuria in pediatric patients.
NCT00741156 ↗ The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution Completed The Hospital for Sick Children Phase 3 2008-07-01 The primary objective of this study is to study the acute effects of angiotensin-converting enzyme inhibitor (ACEI) on systemic, pulmonary and cerebral blood flow in post bidirectional cavopulmonary connection (BCPC) patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Enalapril Maleate

Condition Name

Condition Name for Enalapril Maleate
Intervention Trials
Hypertension 7
Cardiovascular Diseases 2
Breast Cancer 2
Cardiac Toxicity 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Enalapril Maleate
Intervention Trials
Hypertension 9
Essential Hypertension 3
Breast Neoplasms 2
Kidney Diseases 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Enalapril Maleate

Trials by Country

Trials by Country for Enalapril Maleate
Location Trials
United States 28
China 9
Canada 4
United Kingdom 2
Mexico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Enalapril Maleate
Location Trials
Minnesota 1
Massachusetts 1
Arkansas 1
California 1
Connecticut 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Enalapril Maleate

Clinical Trial Phase

Clinical Trial Phase for Enalapril Maleate
Clinical Trial Phase Trials
Phase 4 2
Phase 3 5
Phase 2/Phase 3 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Enalapril Maleate
Clinical Trial Phase Trials
Completed 12
Unknown status 2
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Enalapril Maleate

Sponsor Name

Sponsor Name for Enalapril Maleate
Sponsor Trials
Shenzhen Ausa Pharmed Co.,Ltd 3
University of Minnesota 1
GlaxoSmithKline 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Enalapril Maleate
Sponsor Trials
Other 19
Industry 8
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
McKinsey
Johnson and Johnson
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.